Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) — Working Capital to Net Assets Ratio
Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) has a Working Capital to Net Assets ratio of 76.6% as of March 2026. Working capital of CN¥688.80 Million (current assets of CN¥798.26 Million minus current liabilities of CN¥109.46 Million) is measured against net assets of CN¥899.42 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) financial flexibility to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shenzhen Bioeasy Biotechnology Co. Ltd. Working Capital to Net Assets (2016–2025)
This chart shows how Shenzhen Bioeasy Biotechnology Co. Ltd.'s Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of March 2026, the ratio stands at 76.6%, reflecting working capital of CN¥688.80 Million against net assets of CN¥899.42 Million CNY. See 300942 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Shenzhen Bioeasy Biotechnology Co. Ltd. stock valuation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 72.4% | CN¥657.11 Million | CN¥907.68 Million | CN¥817.81 Million | CN¥160.70 Million | ▲ +3.5 pp |
| 2024 | 68.9% | CN¥599.66 Million | CN¥870.24 Million | CN¥751.62 Million | CN¥151.96 Million | ▼ -1.9 pp |
| 2023 | 70.8% | CN¥600.74 Million | CN¥848.73 Million | CN¥737.67 Million | CN¥136.93 Million | ▲ +21.6 pp |
| 2022 | 49.2% | CN¥474.64 Million | CN¥964.70 Million | CN¥674.42 Million | CN¥199.78 Million | ▼ -29.1 pp |
| 2021 | 78.3% | CN¥741.02 Million | CN¥946.58 Million | CN¥897.64 Million | CN¥156.63 Million | ▼ -3.3 pp |
| 2020 | 81.6% | CN¥448.01 Million | CN¥548.98 Million | CN¥526.13 Million | CN¥78.12 Million | ▼ -13.3 pp |
| 2019 | 94.9% | CN¥501.63 Million | CN¥528.32 Million | CN¥569.72 Million | CN¥68.09 Million | ▼ -7.1 pp |
| 2018 | 102.0% | CN¥227.16 Million | CN¥222.62 Million | CN¥268.66 Million | CN¥41.50 Million | ▼ -5.3 pp |
| 2017 | 107.4% | CN¥123.03 Million | CN¥114.60 Million | CN¥149.25 Million | CN¥26.22 Million | ▼ -23.1 pp |
| 2016 | 130.5% | CN¥72.08 Million | CN¥55.24 Million | CN¥100.84 Million | CN¥28.77 Million | — |